.png)
Mid-size Biopharmaceutical
Market Access, HEOR, Medical Affairs
Pre-Launch
Rare Disease
Subscribe to our newsletter to receive the latest case studies.
Mid-size Biopharmaceutical
Market Access, HEOR, Medical Affairs
Pre-Launch
Rare Disease
A mid-size biopharmaceutical company was entering pivotal development for a rare disease therapy.
As competitors emerged, the team faced uncertainty around how to demonstrate differentiated value and how HTA requirements and modeling expectations would vary across markets.
Without early alignment, differences in evidence thresholds, comparators, and economic assumptions created risk for both access outcomes and launch sequencing.
The client engaged Alkemi to evaluate global HTA requirements, identify gaps, and align HEOR and modeling plans with country-level expectations.
1. Benchmarked HTA processes and evidence requirements across priority markets using competitive analogues.
2. Reviewed evidence and modeling plans to identify gaps, risks, and anticipated payer objections by country.
3. Conducted advisory boards with HTA experts, payers, economists, and KOLs to pressure-test assumptions.
4. Synthesized insights into an aligned HEOR, value modeling, and launch sequencing strategy.
Make modeling decisions early that hold up across markets.
“The Alkemi team refined our HEOR plans and ensured alignment with HTA requirements. This prepared us to tackle payer objections and strengthened our launch strategy.” - Head of Medical Affairs
HEOR plans were refined to reflect priority HTA outcomes and beyond-launch evidence needs.
Confirmed key comparators and country-specific requirements, including the need for ITC modeling in priority markets.
HTA timelines and process insights informed launch sequencing and forecasting assumptions.